The nuclear factor κB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7248-7255

  Hanson, Julie L ^a   Hawke, Noel A ^a   Kashatus, David ^a   Baldwin, Albert S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; GENE INDUCTION; GENETIC TRANSFECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSCRIPTION INITIATION; ANIMAL; CYTOLOGY; FIBROBLAST; GENETICS; MOUSE MUTANT; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; EMBRYO; FIBROBLASTS; GENES, RAS; MICE; MICE, KNOCKOUT; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-REL; RAS PROTEINS; TRANSCRIPTION FACTOR RELA;

EID: 5644264889     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3898     Document Type: Article

References (44)

1. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 2000;12:57-165.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
3. Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE. Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol 2000;20:5381-91.
4. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997;272:24113-6.
5. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Wash DC) 1997;278:1812-5.
6. Norris JL, Baldwin AS Jr. Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J Biol Chem 1999;274:13841-6.
7. Li X, Stark GR. NFkappaB-dependent signaling pathways. Exp Hematol 2002;30: 285-96.
8. Silverman N, Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev 2001;15:2321-42.
9. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109(Suppl): S81-96.
10. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997;89:413-24.
11. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1:661-71.
12. Wang D, Baldwin AS Jr. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem 1998;273:29411-6.
13. Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275:32592-7.
14. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274:30353-6.
15. Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001;276:18934-40.
16. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002;277:3863-9.
17. Langer SJ, Bortner DM, Roussel MF, Sherr CJ, Ostrowski MC. Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol Cell Biol 1992;12:5355-62.
18. Yang BS, Hauser CA, Henkel G, et al. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 1996;16:538-47.
19. Hanson JL, Anest V, Reuther-Madrid J, Baldwin AS. Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways. J Biol Chem 2003;278:34910-7.
20. Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan ME. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 2001; 20:7098-103.
21. Romieu-Mourez R, Kim DW, Shin SM, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003;23:5738-54.
22. Viatour P, Legrand-Poels S, van Lint C, et al. Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. J Biol Chem 2003;278:46541-8.
23. Zhou M, Gu L, Zhu N, Woods WG, Findley HW. Transfection of a dominant-negative mutant NF-kappaB inhibitor (IkappaBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003;22:8137-44.
24. Gapuzan ME, Yufit PV, Gilmore TD. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappaB have a malignantly transformed phenotype. Oncogene 2002;21:2484-92.
25. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Investig 2001;107:241-6.
26. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 1995;270:27894-904.
27. Mahony D, Kalionis B, Antalis TM. Plasminogen activator inhibitor type-2 (PAI-2) gene transcription requires a novel NF-kappaB-like transcriptional regulatory motif. Eur J Biochem 1999;263:765-72.
28. Cohen RL, Niclas J, Lee WM, et al. Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Evidence for independent regulation. J Biol Chem 1989;264:8375-83.
29. Sims JE, Williams DE, Morrissey PJ, et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med 2000;192:671-80.
30. Quentmeier H, Drexler HG, Fleckenstein D, et al. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia (Baltimore) 2001;15:1286-92.
31. Papagerakis S, Shabana AH, Depondt J, Gehanno P, Forest N. Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters. Hum Pathol 2003;34:565-72.
32. Ikeda W, Kakunaga S, Itoh S, et al. Tage4/Nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule Nectin-3 and enhances cell migration. J Biol Chem 2003;278:28167-72.
33. Senaldi G, Varnum BC, Sarmiento U, et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci USA 1999;96:11458-63.
34. Tapon N, Nagata K, Lamarche N, Hall A. A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways. EMBO J 1998;17:1395-404.
35. Moisan S, Demers M, Mercier J, Magnaldo T, Potworowski EF, St-Pierre Y. Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype. Leukemia (Baltimore) 2003;17:751-9.
36. Walter SA, Cutler RE Jr, Martinez R, Gishizky M, Hill RJ. Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue. J Biol Chem 2003;278:18221-8.
37. Ruiz-Arguelles G, San Miguel J. Cell surface markers in multiple myeloma. Mayo Clin Proc 1994;69:684-90.
38. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-57.
39. Gilmore TD. The Rel/NF-kappaB/IkappaB signal transduction pathway and cancer. Cancer Treat Res 2003;115:241-65.
40. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003; 13:107-14.
41. Chadeneau C, LeCabellec M, LeMoullac B, Meflah K, Denis MG. Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas. Int J Cancer 1996;68:817-21.
42. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94:148-52.
43. Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S. Polo-like kinase1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 2000;269:352-6.
44. Rocha S, Campbell K, Perkins N. p53 and Mdm2-independent repression of NF-kappaB transactivation by the ARF tumor suppressor. Mol Cell 2003;12:15-25.